Your browser doesn't support javascript.
loading
The efficacy of Crocus sativus (Saffron) versus placebo and Fluoxetine in treating depression: a systematic review and meta-analysis.
Khaksarian, Mojtaba; Behzadifar, Masoud; Behzadifar, Meysam; Alipour, Maryam; Jahanpanah, Firouzeh; Re, Tania Simona; Firenzuoli, Fabio; Zerbetto, Riccardo; Bragazzi, Nicola Luigi.
Afiliación
  • Khaksarian M; Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
  • Behzadifar M; Department of Physiology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
  • Behzadifar M; Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
  • Alipour M; Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
  • Jahanpanah F; Department of Epidemiology, Faculty of Health and Nutrition, Lorestan University of Medical Sciences, Khorramabad, Iran.
  • Re TS; Faculty of Biological Science & Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Firenzuoli F; Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
  • Zerbetto R; Department of Experimental and Clinical Medicine, Center for Integrative Medicine, Careggi University Hospital, University of Florence, Florence, Italy.
  • Bragazzi NL; Centro Studi Terapia della Gestalt (CSTG), Milan, Italy.
Psychol Res Behav Manag ; 12: 297-305, 2019.
Article en En | MEDLINE | ID: mdl-31118846
Background: Depression represents a serious public health concern, imposing a high burden, both in epidemiological and clinical terms. Crocus sativus (Saffron) is a herbal remedy that has anti-cancer, anti-oxidant, anti-inflammatory and anti-platelet properties. However, the exact mechanisms of Saffron in treating depression are not yet clear. This study was conducted to evaluate the effectiveness of Saffron versus placebo and Fluoxetine in the treatment of depressed patients. Methods: Different bibliographic thesauri, namely the Cochrane Library, Scopus, PubMed/MEDLINE, Centre for Reviews and Dissemination (CRD), EMBASE, and ISI/Web of Science (WoS) were searched up to May 2018. Effect sizes were computed as Standardized Mean Differences (SMD) with their 95% confidence interval (CI). To evaluate the heterogeneity among the studies, I2 test was carried out. Results: Eight studies were included. The SMD was -0.86 (95% CI: -1.73 to 0.00) concerning the comparison of Saffron with placebo. The SMD was found to be 0.11 (95% CI: -0.20 to 0.43) concerning the comparison of Saffron with Fluoxetine. In both sensitivity analyses, the results did not statistically change, confirming the stability of the findings. Conclusion: The findings of this study showed that Saffron administration was well comparable with Fluoxetine and placebo.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Systematic_reviews Idioma: En Revista: Psychol Res Behav Manag Año: 2019 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Nueva Zelanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Systematic_reviews Idioma: En Revista: Psychol Res Behav Manag Año: 2019 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Nueva Zelanda